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Abstract 
Barriers to therapeutic transport in biological systems can prevent accumulation of drugs at the 
intended site, thus limiting the therapeutic effect against various diseases. Advances in 
synthetic chemistry techniques have recently increased the accessibility of complex polymer 
architectures for drug delivery systems, including branched polymer architectures. In this 
contribution, we first outline drug delivery concepts, and then define and illustrate all forms of 
branched polymers including highly branched polymers, hyperbranched polymers, dendrimers, 
and branched-linear hybrid polymers. Many new types of branched and dendritic polymers 
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continue to be reported, however there is often confusion about how to accurately describe 
these complex polymer architectures, particularly in the interdisciplinary field of nanomedicine 
where not all researchers have in-depth polymer chemistry backgrounds. In this context, the 
present review describes and compares different branched polymer architectures and their 
application in therapeutic delivery in a simple and easy to understand way, with the aim of 
appealing to a multidisciplinary audience. 
 
1. Introduction 
 
Drug discovery and development is the process of finding new pharmaceutical candidates and 
bringing them to market, and includes identifying new drug molecules, pre-clinical research, 
clinical trials, and the task of obtaining relevant regulatory approvals.1,2 Recent estimates put 
the average cost of this research and development in the region of 10’s of millions to billions 
USD.3 Historically this R&D has focused on small organic molecule new chemical entities, but 
has now expanded to recent biotech drugs, such as, peptides, proteins, antibodies, and nucleic 
acids. 4,5 
However, these pharmacologically active agents are not necessarily effective in their most 
simple forms due to a number of biological barriers which can limit the therapeutic efficiency.6-
10 Therapeutics are typically administered in formulations to increase their efficacy by 
controlling solubility, absorption, hydrolytic or enzymatic degradation, pharmacokinetics, 
biodistribution, excretion, and off-target toxicity.11-13 A wide variety of materials have been 
developed as formulations and drug delivery systems, with the choice of material selected 
depending on the type of drug, conjugation/release strategies, and  route of administration.14-16  
Materials chemists can elegantly engineer materials of various sizes, shapes, compositions and 
physicochemical properties.17-20 Inorganic materials such as iron oxide nanoparticles, carbon 
nanotubes, metal organic frameworks, and mesoporous silica constructs, have been applied 
with good effect.21 Biological materials are also being investigated including viral vectors for 
the delivery of gene-based therapeutics, and more recently extracellular vesicles have been 
receiving interest for drug delivery.22-24 Among the materials developed for drug delivery 
systems, polymers have possibly been studied the most. Advances in synthetic polymer 
chemistry and coupling techniques, have led to the ability to precisely control both 
nanomaterial composition and function.  
4 
 
As well as looking at different compositions of drug and gene delivery polymers, varying 
architecture has also been investigated.25-28 Research on differing polymer-based nucleic acid 
transfection systems has led to a variety of insights into possible architectural and design 
parameters that could lead to the optimal non-viral delivery agents.29,30 In particular, graft, star, 
and branched polymer systems appear very promising, due to reports of low toxicity and high 
transfection efficiencies.31 Branched polymers also offer benefits related to multifunctionality, 
which can offer synthetic routes to multivalent ligand display and also increased possibilities 
for covalent drug attachment. The multifunctionality of branched and dendritic architectures 
also opens the door to new opportunities for theranostic applications (combined diagnostic as 
well as therapeutic).32  
Many new and creative examples of branched and dendritic polymers continue to be reported, 
but there is often confusion about how to accurately class these complex polymer architectures. 
In this review, we first outline therapeutic delivery concepts and guiding principles in 
overcoming certain biological barriers. We then define, illustrate, and outline synthetic 
strategies for all possible forms of branched polymers including highly branched polymers, 
hyperbranched polymers, dendrimers, and branched-linear hybrid polymers. A selection of the 
most important recent examples of branched polymers in drug delivery applications will be 
highlighted and discussed, with a particular focus on the ability to control polymer 
composition, degradability, shape, and external functionality. Overall, the present review 
describes and compares different branched polymer architectures and their recent (primarily 
post 2015) application in therapeutic delivery in a simple and easy to understand way, with the 
aim of appealing to a multidisciplinary audience. A number of excellent reviews cover more 
specific details of dendrimer and hyperbranched polymer synthesis,33,34 or biological 
applications of these polymers in great depth,32,35-39 should the readership be interested in 
further information.  
 
2. Biological barriers to therapeutic delivery 
 
In order to achieve therapeutic effect, pharmacologically active molecules need to reach their 
sites of action, typically on a cellular level, and with a high enough dose or concentration. 
However there are a number of hurdles to successful therapeutic delivery, including both 
extracellular and intracellular barriers.40-42 Many recent efforts have involved designing 
particles and delivery systems with certain properties or stimuli response to specifically 
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overcome some of these barriers,43 while others have focused on increasing fundamental 
understanding of these clearance mechanisms.10 
2.1. Extracellular barriers 
In case of oral, inhalation, and some local administration routes, a major barrier to drug delivery 
are mucus layer barriers. Mucus coat regions include the gastrointestinal tract, lung airways, 
vaginal mucus membranes, and nasal cavities, and is composed of a viscoelastic mucin fibre 
hydrogel.44 These mucus gels are typically negatively charged due to sialic acids and sulfate 
groups in the sugar fibre chains, and contain many different salts, proteins, bacteria, lipids, and 
other species which form a complex network which protects the underlying cells from external 
species including nanoparticle systems.45,46 Oral delivery routes also have the added barrier of 
harsh stomach and intestine pH conditions which can hinder the delivery and stability of 
therapeutics.13 
In the case of systemic routes of administration directly into the circulatory system, these 
potential hurdles can be avoided. However, there are further barriers to be navigated, including 
avoidance of polymer aggregation and destabilisation in blood which could occur with non-
specific protein adsorption and also red blood cell association and aggregation.47 Enzymatic 
drug degradation is recognized as a growing problem with regard to antibiotic resistance, as 
one of the mechanisms by which this resistance occurs is through bacteria production of 
enzymes that selectively target and destroy the activity of antibiotics.48 In addition, enzymatic 
degradation of nucleic acids has been reported to occur within the order of minutes in vivo, 
which is a major challenge for gene therapy treatments.49,50 
During circulation drug delivery systems are subject to physical clearance by lung, slpeen 
hepatic, and renal pathways.41 Elimination of larger injected material occurs via fenestrations 
in the pulmonary capillaries and sinusoids of the lungs and spleen respectively. In the liver, 
polymers, biopharmaceuticals, and nanoparticles with sizes <200 nm are primarily cleared by 
liver sinusoidal endothelial cells, and particles of larger sizes (>200 nm) or higher rigidity are 
generally taken up by Kupffer cells.51 The kidneys are responsible for removal of the smallest 
sized particles, proteins, or foreign bodies from blood (<5 nm).  
The inevitable interaction of nanoparticles with the immune system poses a number of 
problems, including opsonization and clearance by the mononuclear phagocyte system (MPS), 
and also pro-inflammatory response to certain nanomedicines.52,53 Opsonization involves the 
binding of an antibodies or proteins to the drug delivery vehicle surface, and subsequent 
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recognition and sequestration by phagocytes - either resident macrophages in the spleen or 
liver, or circulating macrophages. The formation of this protein corona is dependent on 
nanoparticle size, surface charge, and exterior chemical composition.54,55 A common strategy 
is to functionalise the nanocarrier exterior with a stealth non-fouling polymer such as 
poly(ethylene glycol) (PEG), poly(poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC), 
poly(2-oxazoline) (Pox), or poly(poly(ethyl ethylene phosphate) (PEEP).56,57 These 
hydrophilic polymers form a hydration layer which can hinder protein absorption and thus 
reduce MPS clearance. 
 
Figure 1. Barriers in the delivery pathway of polymer based nanomedicines, a) formation of therapeutic 
conjugate/complex with polymer b) avoidance of rapid clearance and unspecific interactions with blood 
components, c) cellular uptake, therapeutic release, and intracellular trafficking. 
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Polymer and other nanoparticle based therapeutics need to extravasate from the circulatory 
system and cross the vasculature endothelium in order to reach their intended site of action. 
This can occur by passive endothelial transcytosis, but also occurs via the enhanced permeation 
and retention (EPR) effect described by Maeda and colleagues.58,59 The EPR effect is due to 
blood vessel dysfunction and fenestrations at sites of tumours, and has been utilized to 
passively target cancerous tissue and enhance nanoparticle accumulation.60 
Although great advances have been made using polymeric drug delivery systems for 
therapeutic delivery to tumours and other non-brain organs, the central nervous system (CNS) 
is a particular challenge for drug delivery.61 The blood brain barrier significantly restricts the 
passage of systemically delivered therapeutic drug molecules to the brain; the benefits of 
polymeric nanoparticles represent a promising solution to these problems but have yet to be 
fully exploited.62,63 The role of this barrier is to regulate the homeostasis of the brain, and thus 
maintain the unique extracellular environment of the CNS. Structurally, the BBB consists of 
endothelial cells which form the walls of the capillaries of the brain and spinal cord.64 There 
are tight continuous junctions between these particular endothelial cells, which restricts any 
aqueous paracellular passages from the blood. Small molecules and also larger biomolecules 
and nanoparticles can only access the CNS by a transcellular mechanism through the 
vasculature endothelium. This primarily requires harnessing of various endogenous transport 
systems and receptors in the capillary endothelium. The different mechanisms for endogenous 
transport across the BBB can be categorised generally as: the transcellular lipophilic pathway; 
use of transport proteins (utilized by glucose and amino acids); receptor mediated transcytosis 
(utilized by transferrin and insulin);65 and absorptive transcytosis.64 
 
2.2. Intracellular barriers 
After a period of circulation and extravasation, nanocarriers need to be uptaken by target cells 
after which release of therapeutic payload can occur in order for the active agent to achieve 
therapeutic effect on the relevant cytosol, nuclear, or intracellular organelle objective. Cellular 
internalization can occur via the mechanisms of passive diffusion or various endocytic 
pathways, such as macropinocytosis, receptor mediated endocytosis, or phagocytosis.66 The 
initial step involves particle interaction with components of the outer surface of cells, and then 
formation of internalized vesicle structures of various sizes and internal environments. This 
process of crossing cellular membranes can depend to a large extent on size, charge, and surface 
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morphology of the species being internalised, but also the nature of the cell-type in question. 
Naked nucleic acids and other biomacromolecules can often be too negatively charged to enter 
cells efficiently via endocytosis.67 Attempts to increase internalisation include moderation of 
particle surface charge and hydrophobicity, with cationic species reportedly being uptaken 
significantly more, but also have higher toxicity due to non-specific membrane lysis.68 
Attachment of ligands to drug delivery systems is also a popular method of enhancing uptake 
in certain cells expressing the appropriate cell surface receptors. 
Once inside the cell, the delivery vehicle then needs to escape from the endosome.69 Endosome 
escape is essential for the avoidance of lysosomal degradation of therapeutic molecules from 
lysozyme enzymes and acidic pH environment. Endosomal escape of nanomedicines is also 
required to avoid the eventual exocytosis of internalized material. Other approaches include 
the incorporation of pH responsive functionalities designed to become cationic at the reduced 
endosomal pH values, thus triggering membrane interaction and rupture, and escape of the drug 
delivery system to the cytosol.70-72 Following progression of the drug delivery system to the 
cytosol, the final stages for optimal therapeutic delivery and efficiency involve release of 
therapeutic from the nanocarrier, either for the mechanism of action to occur in the cytosol, or 
for diffusion to the appropriate cellular organelle. A number of elegant conjugation chemistries 
have been developed for precise therapeutic release in response to certain cellular environments 
or stimuli, including redox responsive disulfide bonds which are known to cleave in the 
presence of intracellular levels of glutathione.73,74 For successful DNA transfection the DNA 
needs to pass the double membrane nuclear envelope and enter the nucleus to be transcribed. 
Entry to the nucleus occurs through the nuclear pore complex through either passive or active 
transport mechanisms, again, with size being a determining factor.75-77 
 
3. Polymer architectures for therapeutic delivery 
 
3.1. Increasing complexity 
Polymers have a key role in drug delivery systems and have the potential to provide solutions 
by simplifying administration, reducing toxicities, and improving efficiencies through 
additional functionality.78 The progression of polymer architectures from linear to more 
complex branched topologies by use of easily accessible chemistries while maintaining 
reasonably large scale production, offers further opportunities to improve therapeutic 
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delivery.25,79 Recent advances in polymer chemistry, including new step-growth 
polymerisation routes, continued advancement of controlled radical and ring-opening 
polymerisation methods, and further development of simple, high yielding, and orthogonal 
coupling chemistries, has brought unprecedented access to complex polymer architectures.80,81 
Branched polymers are a special class of polymer architecture characterised by their high 
branching densities.33 The branched polymer topology imparts a number of favourable 
properties compared to their linear polymer equivalents including: high surface functionality, 
globular conformation, low intrinsic viscosities, high solubilities, and interesting rheological 
modifying properties.33,34,82 This has led to branched polymers being increasingly important 
for biomedical applications over the past 20 – 30 years.35,83  
 
Figure 2. Cartoon representation of various branched polymer architectures able to be synthesised 
with modern polymerisation and coupling synthetic strategies. 
 
In certain polymers such as thermosets and rubbers, branching is typically on a 
macrocscopic/crosslinked scale, leading to interesting physical properties of these materials. 
This review focuses of branching in soluble nanoscale forms, and will refer to branched 
polymers of the following definitions (illustrated in Figure 2). The term highly branched 
polymer refers to high frequency main chain branching of linear polymers, with the branch 
points in a highly branched polymer being distributed randomly throughout the polymer. The 
major advantage of highly branched polymers is their simple synthetic methodologies. In 
general, the term dendritic polymer is used to refer to a class of branched polymers including 
dendrimers, dendrons, hyperbranched polymers, and hybrid variants containing dendrons and 
hyperbranched polymers. The term originates from the Greek word dendron, δένδρον, which 
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translates to tree. The various subclasses of dendritic polymers can be further defined. 
Dendrimers were first synthesised in laborious multi-step procedures, in the late 1970’s and 
early 1980’s, and are defined by their perfectly symmetrical and layered branching patterns 
(with no irregular or non-branching points, DB), and therefore single molecular weight with a 
dispersity of 1.84-86  
𝐷𝐵 =
𝐷 + 𝑇
𝐷 + 𝑇 + 𝐿
        (𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟏) 
Degree of branching (DB) was defined by Fréchet and coworkers, Equation 1, where D, T and 
L are the fractions of dendritic, terminal or linear monomer segments in the resulting dendritic 
polymers (obtained from NMR spectroscopy).87 Dendrimers have DB’s of 1. Hyperbranched 
polymers are synthesized by step-growth polymerization via condensation or addition of ABn 
monomers in one-pot reactions. Here, A and B are the two functionalities that can react with 
each other but not with themselves. In an AB2 monomer system, the degree of branching is 
controlled by statistics and only reaches around 0.5, far from the value of 1 usually achieved 
with dendrimers.88 Further functionality and control over branching distributions can be 
introduced by the AB2 polymerisation of macromonomers leading to long chain hyperbranched 
polymers.89 Recently, evolution of these branched topologies has progressed towards dendritic-
linear hybrid polymers from combination of well controlled linear polymers with dendritic 
polymers, via creative coupling and polymerisation chemistries.90 These structures include 
linear hybrids of dendrimers and hyperbranched polymers, and can be in the form of branched-
linear block copolymers, branched-core star polymers, and dendronised polymers. 
From a synthetic chemistry perspective, these structures can by produced from an ever 
expanding toolbox of polymer chemistry and coupling chemistry techniques. A summary of 
these procedures can be found in Figure 3. Dendrimer formation has typically proceeded using 
a series of iterative growth and activation steps.91 Dendrimers can be synthesized following the 
divergent approach which can lead to branching irregularities at higher generations, and also 
the convergent approach, which was introduced in pioneering work by Fréchet and Hawker 
and can lead to higher purity.92 Due to their structural precision this has been achieved with 
robust organic reactions, including amidification and esterification reactions (Figure 3). 
Recently improvements to dendrimer synthesis, in terms of reaction times and purity, have 
been achieved using accelerated techniques based on efficient and orthogonal chemistries.93 
11 
 
 
Figure 3. Schematic representations of some of the synthetic strategies to achieve branched polymer 
architectures with modern polymerisation and coupling synthetic strategies: a) branched and linear 
polymers via step growth polymerisations, i) esterification condensation, ii) amidification 
condensation, iii) thiol-ene addition, iv) thiol-yne addition, v) asymmetric epoxide ring opening, vi) 
michael addition type, b) branched and linear polymers via controlled chain growth polymerisations, 
i) living anionic, ii) Cu(0) radical polymerisations, iii) ring opening polymerisations, iv) RAFT 
polymerisation, c) various coupling strategies for formation of branched-linear hybrid materials, and 
also therapeutic conjugation, i) ester, ii) amide, iii) michael addition, iv) thiol-ene, v) thiol-yne, vi) 
azide-alkyne cycloaddition, vii) disulfide formation, viii) hydrazone.  
 
 
One-pot synthetic strategies for formation of highly branched and hyperbranched polymers 
arose as an alternative and simpler route to polymers with similar favourable properties to 
dendrimers, but without demanding multi-step syntheses and purifications. Hyperbranched 
polymers are synthesised by the step growth polymerisation of ABn monomers (where n ≥ 2), 
and also the step growth copolymerisation of combinations of monomers, as in the A2 + Bm  
approach (where m ≥ 3).33 These reactions were theorised by Flory decades ago and require 
monomers different A and B functionalities that can react with each other but not with 
themselves.94 Step growth polymerisations can also be performed with telechelic AB2 
macromonomers leading to long chain hyperbranched polymers.95 
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The design and synthesis of highly branched polymers by chain growth polymerisations is a 
more recent development in polymer chemistry. In the self-condensing vinyl polymerisation 
(SCVP) route, which was introduced by Fréchet and co-workers, a vinyl monomer bearing an 
initiating group can propagate through the vinyl bond and also form branching points through 
the initiating group.96 This SCVP has been extended to RAFT, ATRP, NMP, and SCROP. 
Another popular chain growth strategy for highly branched polymers is the Strathclyde route, 
which involves the copolymerisation of vinyl monomers with small amounts of divinyl 
monomers and in the presence of a chain transfer agent.97 Similarly to SCVP, this method has 
also been extended to the controlled radical polymerisations RAFT and ATRP. Linear 
polymers with pendant vinyl moieties are formed, which then have the opportunity to 
polymerise into other linear chains to form highly branched polymers. 
Since the development of living anionic polymerisations by Szwarc in 1956, there have been 
many chain growth polymerisations developed for synthesis of linear polymers with controlled 
molecular weights, narrow molecular weight dispersities, and precise functionality.98,99 RAFT 
polymerisation in particular is becoming increasingly popular for biomedical applications, in 
part due to its ease of use and compatibility with a wide range of monomers.100 In addition to 
synthesis of highly branched polymers by chain growth methods as mentioned previously, by 
combining these chain growth systems with efficient coupling chemistries, researchers can now 
easily synthesise new types of branched-linear hybrid architectures including, branched-linear 
block copolymers, branched-core star polymers, and dendronised polymers. The expansion of 
highly efficient coupling chemistries, after the seminal work of Sharpless et al., has led to 
further options for synthesis of these types of architectures.101 Available click-type reactions 
include, the Huisgen alkyne-azide cycloaddition, thiol-ene/yne radical additions, various thiol-
ene Michael additions, and tertiary isocyanate amine coupling among others.80,102 
Therapeutic molecules can be carried by these polymer systems by two main methods: 
encapsulation with either hydrophobic or electrostatic interactions, and also covalent 
attachment to the polymeric carrier. Encapsulation methods have been widely investigated, and 
branched polymer architectures offer the benefits of having globular three-dimensional 
topologies capable of encapsulating high loadings of cargo. A benefit of this approach is the 
ability to obtain unimolecular micelle type of structures without concentration dependent 
disassembly at low concentrations.36 However it can be difficult to control the release of 
molecules from the polymer. Many interesting chemistries (Figure 3) have been developed for 
covalent attachment guest molecules, including stimuli responsive linkers able to release 
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therapeutic molecules on certain specific triggers, including pH, redox environments, glucose, 
and enzymatic cleavage.43 Branched polymers also offer advantages for this drug attachment 
method, due to their high number of functionalisable groups on the periphery of the constructs.  
It is worth noting that branched and dendritic polymers have also gained use as active 
ingredients themselves, without the need for additional therapeutic molecules. For example, in 
the treatment of inflammatory and autoimmune diseases such as rheumatoid arthritis and 
multiple sclerosis, dendrimers and hyperbranched polymers have been used as anti-
inflammatory agents.103-105 Dendrimers are also emerging as treatments of infections, based on 
antimicrobial activity of the polymer itself.106 Currently Starpharma dendrimer product 
Vivagel® has completed phase III trials, and been launched in multiple countries, for topical 
treatment and rapid relief of bacterial vaginosis. In addition carbosilane dendrimers with 
sulfonate end groups,107 and phosphorous based dendrimers with cinnamic acid terminating 
groups,108 have been investigated as HIV-1 retrovirucides. 
 
Table 1. Summary of current state-of-the-art in branched polymer therapeutic delivery systems, 
including design strategies for various branched polymer architectures, and specific application details 
in drug/ gene delivery. 
Architecture Structure 
Polymer synthetic 
method 
Therapeutic 
conjugation 
method 
Application Ref 
 
Highly branched 
Divinyl 
copolymerisation  
RAFT 
copolymerisation with 
divinyl monomer 
Electrostatic 
nucleic acid 
complexation 
Plasmid DNA 
delivery 
109 
 
 
RAFT 
copolymerisation with 
divinyl monomer 
Electrostatic 
nucleic acid 
complexation 
Controlled release 
of dsRNA 
110 
 
 
 
 
ATRP 
copolymerisation with 
divinyl monomer 
Encapsulation of 
SPIONs 
SPION delivery 
for 
therapy/diagnosis 
111 
 
 
RAFT 
copolymerisation with 
divinyl monomer 
Electrostatic 
nucleic acid 
complexation 
Plasmid DNA 
delivery 
112 
 
 
ATRP 
copolymerisation with 
divinyl monomer 
Electrostatic 
nucleic acid 
complexation 
Plasmid DNA 
delivery 
113 
SCVP 
 
ATRP SCVP of 
degradable inimer and 
DMAEMA 
Drug 
encapsulation 
Niclosamide and 
amonafide drug 
delivery 
114 
14 
 
 
 
RAFT SCVP of 
disulfide inimer and 
PEGMA/aptamer 
monomer 
 
Hydrophobic drug 
encapsulation 
 
Delivery of 
doxorubicin to 
breast cancer cell 
line 
115 
 
 
 
 
RAFT SCVP of 
disulfide inimer and 
PEGMA/GMA 
Covalent 
attachment, with 
acid and redox 
cleavable groups 
Camptothecin 
intracellular 
delivery 
116 
 
 
RAFT SCVP of 
disulfide inimer and 
functional monomers 
Disulfide linked 
drug monomer 
(Gd MRI imaging 
via epoxide) 
Camptothecin 
intracellular 
delivery 
117 
 
Hyperbranched 
 
ABn 
 
AB2 polycondensation 
(isocyanate-hydroxy) 
Covalent 
attachment 
Doxorubicin 
delivery and DNA 
delivery 
118 
 
 
 
 
AB2 polycondensation 
Hydrophobic drug 
encapsulation 
Taxol anticancer 
therapy 
119 
 
 
AB2 ROP of epoxide 
containing glycidol 
Enzyme cleavable 
covalent 
attachment 
Doxorubicin and 
methotrexate 
anticancer drugs 
120 
 
 
 
AB3 ROP of epoxide 
containing monomer 
 
Ester linked 
covalent 
attachment 
Methotrexate 
anticancer drug 
121 
 
A2+Bm 
 
 
A2 +B3 
Michael addition 
Electrostatic 
nucleic acid 
complexation 
Tumour siRNA 
delivery in vivo 
122 
 
 
A2 +B2 +B3 
polycondensation 
Cell penetrating 
peptide mimic 
Intracellular 
delivery via 
endosome 
disruption 
123 
 
 
 
 
A2 +B2 +B3 
Michael addition 
Electrostatic 
nucleic acid 
complexation 
Plasmid DNA 
delivery for skin 
gene therapy 
124 
Longchain 
hyperbranched 
 
Proton transfer AB2 
polymerisation 
Ester linked 
covalent 
attachemnt 
Methotrexate 
anticancer drug 
125 
 
 
 
 
CROP and thiol-yne 
AB2 photoaddition 
polymerisation 
Electrostatic 
nucleic acid 
complexation 
Plasmid DNA 
delivery 
126 
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A2 +B4 Michael 
addition 
polymerisation 
 
Electrostatic 
nucleic acid 
complexation 
Plasmid DNA 
delivery 
127 
 
 
CROP and thiol-yne 
AB2 photoaddition 
polymerisation 
 
Hydrophobic drug 
encapsulation 
Doxorubicin drug 
release in vitro 
128 
 
Dendrimer 
 
 
 
Divergent dendrimer 
synthesis 
(commercial) then 
Michael addition 
modification 
Electrostatic 
nucleic acid 
complexation 
siRNA gene 
delivery to lung 
vasculature 
129 
 
 
Divergent strategy 
using standard peptide 
coupling chemistry 
 
Electrostatic 
nucleic acid 
complexation 
Plasmid DNA 
delivery 
130 
 
 
 
 
Divergent dendrimer 
synthesis 
(commercial) then 
activated ester 
coupling 
 
Disulfide linked 
covalent 
attachment 
NAC anti-
inflammatory 
agent delivery to 
B2-V microglial 
cells 
131 
 
 
G4 PPI dendrimer 
Reductive amination 
coupling of maltose 
shell 
Electrostatic drug 
complexation 
Fludarabine 
triphosphate 
delivery 
132 
 
 
 
 
Divergent dendrimer 
synthesis 
(commercial) then 
amide coupling 
Disulfide linked 
covalent 
attachment 
NAC and valproic 
acid anti-
inflammatory 
133 
 
Branched-linear 
hybrid 
 
Branched-linear 
block 
  
Divergent lysine 
dendron synthesis and 
amidification with 
PEG and functionality 
Hydrophobic drug 
encapsulation 
Delivery of 
doxorubicin to 
lymphoma tumour 
134 
 
 
 
 
NCA ROP, divergent 
dendrimer synthesis, 
activated ester 
coupling 
Hydrophobic drug 
encapsulation 
Paclitaxel drug 
delivery 
135 
 
 
Commercial PEG, 
divergent dendrimer 
synthesis, activated 
ester coupling 
Disulfide linked 
covalent 
attachment 
Camptothecin 
delivery in vivo 
136 
16 
 
 
 
Alkyne azide click 
coupling of PAMAM 
dendrons and PEG 
Hydrophobic drug 
encapsulation 
Doxorubicin 
encapsulation and 
release 
137 
Branched-linear 
star 
 
 
Polycondensation 
(commercial H40) ph 
sensitive polypeptide 
shell coupling 
Electrostatic 
nucleic acid 
complexation 
siRNA gene 
delivery 
138 
 
 
 
 
CROP and thiol-yne 
photoaddition 
polymerisation 
Hydrophobic drug 
encapsulation 
Hydrophobic dye 
as drug model 
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Polycondensation 
(commercial H40) 
activated ester PEG 
arm coupling 
Hydrophobic drug 
encapsulation 
Doxorubicin 
anticancer drug 
delivery 
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Azirine ROP 
(commercial PEI) 
Michael addition arm 
coupling 
Electrostatic 
nucleic acid 
complexation 
Plasmid DNA 
delivery 
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ATRP with divinyl 
comonomer 
Electrostatic 
nucleic acid 
complexation 
siRNA gene 
delivery to lung 
vasculature 
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Dendronised 
 
 
Divergent lysine 
dendron synthesis and 
azide alkyne click 
coupling to heparin 
Covalent 
attachment, 
through acid 
cleavable 
hydrazone 
Doxorubicin 
delivery in 4T1 
breast tumor 
model 
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Polystyrene based 
backbone grafted with 
polyester dendrons 
In vivo 
biodistribution 
studies with 
radiolabel 
Radiolabel as 
proof-of-concept 
for drug delivery 
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PEG azido polymer 
backbone grafted with 
polyglycerol dendrons 
Hydrophobic drug 
encapsulation 
Hydrophobic dye 
as drug model 
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3.2. Highly branched polymers 
Synthesis of highly branched polymers by use of chain growth polymerisations, is a versatile 
and scalable approach for the synthesis of functional polymers.146 Radical chain growth 
polymerisation methods have always produced branching in some cases through the radical 
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polymerisation side reactions of intramolecular backbiting, intermolecular transfer to polymer, 
and polymerisation of vinyl terminated disproportionation products.147 However, introduction 
of branching in radical polymerisations through design was more recently established.  
 
3.2.1. Divinyl monomer copolymerisation 
Network formation through the radical polymerisation of vinyl monomers with difunctional 
comonomers is analogous to step growth polymerisations of multifunctional monomers. These 
polymerisations have been considered theoretically by Flory and Stockmayer, among 
others.148-151 Whilst considerable experimental work has also been carried out with various 
monomer pairs, including: MMA and EGDMA, styrene and divinyl benzene, vinyl acetate and 
divinyl adipate. Theory predicts that macroscopic crosslinking will occur when the number of 
difunctional branching monomers per polymer chain is greater than one. In practise there is 
often a discrepancy between the theory and the observed polymerisation gel points. Theoretical 
gel point values are generally underestimated due to pendant vinyl group of the multifunctional 
commoner species causing intramolecular cyclisation during the polymerisation or becoming 
less reactive as one group is polymerised and remaining as an unreacted pendant vinyl group 
throughout the polymerisation.152 These free radical polymerisation systems are often difficult 
to predict and can require considerable optimisation in order to achieve high conversions 
without macroscopic gelation.153,154  
However, in 2000 Sherrington et al., introduced an improvement to free radical 
polymerisations of divinyl monomers to form highly branched but soluble polymer 
architectures, by inclusion of thiol chain transfer agent (CTA).97,155,156 This method, known as 
the ‘Strathclyde route’, reduces the primary chain length, can delay gelation, and can allow 
inclusion of additional functionality through functional CTAs. Atom transfer radical 
polymerisation (ATRP) was then employed to synthesise similar branched polymers with a 
more controlled polymerisation.155 The difunctional copolymer method to branched polymers 
was first employed with reversible addition fragmentation chain transfer (RAFT) 
polymerization by our group in 2005,157,158 and further investigated by Armes and 
coworkers.152 
Early work on application of these branched polymer systems to DNA delivery was established 
by the Davis group, who synthesised highly branched PDMAEMA-b-PEG using RAFT 
polymerisation.159,160 The structures were formed with a redox sensitive divinyl comonomer, 
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to yield high molecular weight polymers able to be cleaved into lower molecular weight 
polymer chains. Efficient binding of DNA was shown to occur through electrostatic 
interactions. This method has also been adopted by the Thurecht group who have used the 
RAFT copolymerisation of DMAEMA and EGDMA to synthesise highly branched structures 
for a variety of biomedical applications including gene delivery.109,161 Polymer ability to deliver 
DNA was investigated using in vitro cell uptake assays in HeLa cells with flow cytometry. 
Branched pDMAEMA conjugated with the targeting ligand Folate (overexpressed on HeLa 
cells) showed improved cell uptake compared to oligofectamine and non-folate branched 
pDMAEMA, however polymer toxicity was observed above N/P ratios of 10. 
More recently, Rannard and Owen, have shown that ATRP copolymerisations with small 
amounts of EGDMA leads to branched polymers which can form stable nanoparticles with 
tuneable sizes and functionalities.162 It was shown, with a gut epithelium model, that these 
nanoparticles are able to cross mucus barriers and have potential of use as orally-administered 
nanocarrier systems. Amphiphilic highly branched polymers were used to stabilise oil-based 
emulsions and deliver different dissolved antiretroviral drugs for HIV/AIDS therapy. Using an 
epithelium monolayer transwell membrane the permeation of emulsion formulated HIV 
protease inhibitor Lopinavir was around 10 times higher than the aqueous application of the 
drug.163 In a viral activity assay the antiviral effect (against HIV-1 IIIB) of drug-loaded 
nanoemulsions was similar to the aqueous based control. Additionally, it has been 
demonstrated that these highly branched polymers, synthesised by ATRP, can form stable 
nanoparticle composites with super-paramagnetic iron oxide nanoparticles (SPIONs) with 
future uses for delivery of drugs, imaging agents, or hyperthermia agents within cancer 
therapies.111  
Wang and coworkers have investigated the effect of branching on transfection of plasmid DNA 
coding for G-luciferase and also green fluorescent protein (GFP).113 Variation of primary chain 
length and density of branching between individual polymer chains was achieved using ATRP 
with redox responsive divinyl comonomer. The authors found that the most highly branched 
polymer had the least adverse cytotoxic effects, whilst having higher transfection efficiencies 
than the linear pDMAEMA control. 
Our group has recently focussed on expanding the application of highly branched polymers by 
RAFT polymerisation as nucleic acid delivery systems, by incorporation of alternative 
functionalities for nucleic acid complexation, and also controlled payload release 
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strategies.110,112 Highly branched polymers containing phosphonium cationic moieties, and also 
the equivalent polymer with ammonium cationic groups, were synthesised by a post 
polymerisation modification route. Bromoethyl acrylate (BEA) and polyethyleneglycol 
acrylate (PEGA) were copolymerised with diacrylate comonomer DEGDA by RAFT 
polymerisation, this precursor was functionalised via the bromine with trimethylphosphine and 
trimethylammonium. The phosphonium polymers showed good ability to complex nucleic 
acids, good biocompatibility, lower cytotoxicity to a NIH-3T3 celline over a polymer 
concentration range from 0.5 µg/mL to 2 mg/mL, and higher GFP transfection efficiencies 
compared to the ammonium equivalent. In another study, we investigated the ability of highly 
branched polymers to complex and release dsRNA in a sustained manner, in vitro, by 
complexation of nucleic acids with highly branched p(DMAEMA-co-DMAEA) (Figure 4). 
By copolymerising we were able to tune the hydrolysis rate of the acrylate side chains, which 
transform from cationic amine containing groups, into anionic acrylic acid groups, therefore 
tuning the release of dsRNA. This release mechanism is also beneficial in terms of cytotoxicity 
compared to cationic pDMAEMA or bPEI, as the polymers hydrolyse over time to 
biocompatible less cytotoxic polyacrylic acid. 
 
 
Figure 4. Highly branched and hydrolysable copolymers by RAFT for dsRNA release, including 
agarose gel electrophoresis assay showing dsRNA release (polyplexes all at N/P ratio 5) over time 
periods up to 28 days a) branched pDMAEA; b) branched p(DMAEMA10-co-DMAEA40); c) branched 
pDMAPA; d) branched p(DMAEMA40-co-DMAEA10); e) branched pDMAEMA; and polymer toxicity 
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to NIH-3T3 cells following 24 hr incubation of f) initial polymers; g) polymers pre-incubated for 2 
weeks in D2O at pH ~ 7.4. Figure adapted with permission 
110. Copyright 2018 Royal Society of 
Chemistry. 
 
3.2.2. Self-condensing vinyl polymerisation 
In 1995, Fréchet et al. showed that polymerisation of a vinyl monomer bearing an initiating 
group allowed polymerisation through the vinyl group and also through the initiating site, 
leading to the formation of highly branched polymers.96 The authors termed this self-
condensing vinyl polymerisation (SCVP). The SCVP process has been extended to various 
chain growth polymerisation methods, such as, nitroxide mediated polymerisation (NMP),164 
reversible addition chain transfer polymerisation (RAFT),165 atom transfer radical 
polymerisation (ATRP),166 and ring opening polymerisation (ROP).167,168 Chain growth 
methods to highly branched polymers, such as divinyl commoner method, and SCVP, allow 
for facile incorporation of stimuli responsive groups, prodrug monomers, and imaging moieties 
for theranostic applications.169 
The group of Gao has investigated branched polymers by SCVP for breast cancer therapies. 
The researchers used ATRP of inimers in microemulsion, and were able to load a drug 
combination of DNA damage repair agents and also STAT-3 inhibitors (amonafide and 
niclosamide respectively).114 Selective and synergistic growth inhibition of triple negative 
breast cancer cells (IC50 of 2-4 times lower than the individual drugs) was seen with the 
combination of drugs encapsulated in the branched polymer delivery system. Luo et al., 
synthesised branched hydroxypropyl methacrylamide copolymers by a RAFT SCVP method, 
incorporating a DOX prodrug monomer and cathepsin-B enzyme cleavable branching units.170 
The high molecular weight and large (102 nm diameter) branched polymers could be degraded 
into lower molecular weight and smaller (8.2 nm diameter) species. These branched drug 
conjugates were investigated for breast cancer therapy both in vitro and with a mouse model. 
Enhanced antitumour efficacies in a 4T1 tumour model was observed by TG1, 
immunohistochemical results, and the in vivo toxicity assays, highlighting potential benefits of 
designing polymer drug delivery systems with stimuli responsive and degradable properties 
compared to the non formulated free drug. Recently RAFT SCVP was also employed by Wei 
and colleagues, to form highly branched polymer prodrug conjugates with both redox sensitive 
disulphide groups and acid sensitive groups carbonate groups.116 The presence of acidic pH 
conditions or glutathione environments enhances the release of camptothecin, with the polymer 
system having IC50 values of 365.1 g/ml, to HeLa cell-line with an MTS cell viablilty assay. 
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3.3. Hyperbranched polymers 
Hyperbranched polymers have a more defined branching pattern than highly branched 
polymers, as branch points are introduced at high proportion of monomer units, compared to 
randomly along a chain growth polymer chain with highly branched polymers.82 This feature 
makes hyperbranched polymers interesting for therapeutic delivery applications as the degree 
of branching in terms of branching units, linear units, and terminal units is much more easily 
defined and characterised.34  
 
3.3.1. Step growth polymerisation of ABn monomers 
Much of the theory of branched and hyperbranched polymers was outlined by Flory in the mid-
20th century, based on polycondensation reactions.94 In order for ABn hyperbranched polymers 
to be formed, a number of requirements were outlined by Flory: the A moiety must react 
selectively with B groups, B groups must have equal reactivity, and no cyclisation reactions 
should occur. These reactions proceed in a manner similar to most step growth polymerisations 
with rapid loss of monomer early in the reaction, high conversions required for high molecular 
weights, and the case of ABn polymerisations there is no possibility of crosslinking (in theory). 
The resulting polymers contain dendritic units (fully reacted B moieties), linear units (singly 
reacted B moieties), terminal units (unreacted B moieties), and one focal A group. One of the 
most well-known examples of a hyperbranched polymer formed from ABn polycondensation 
is the commercial polymer Boltron, synthesised from the monomer bis(methylol)propionic 
acid (bis-MPA).171 Boltron hyperbranched polymers with multiple surface hydroxyl functional 
groups have been synthesised, which have been used in a large number of applications, both as 
the native polymer and also post-polymerisation modified via the hydroxyl groups to impart 
further functionality or different solubility properties.172 In this case control over the reaction 
(resulting molecular weight, molecular weight distribution, and degree of branching) can be 
achieved by addition of monomer in discrete portions, later developed into the ‘slow monomer 
addition’ method.173,174 
Klok et al. have investigated the effect of degree of branching of polylysine on DNA 
complexation and delivery.130 Transfection efficiency was affected by both polymer 
architecture and molecular weight. At similar molecular weights the hyperbranched 
polylysines showed greater transfection and gene knockdown compared to their linear and 
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dendrimer analogues. In the 1990’s, Mulhaupt and Frey developed the chemistry of 
hyperbranched polyglycerols which are formed from the step growth polymerisation of 
glycidol, a latent AB2 monomer.
175 The polymers have very high biocompatibility Over many 
studies the polymers have displayed low cytotoxicity both in vitro and in vivo,176 similarly to 
the established linear polyethylene glycol, however great control over the branching and 
architecture can be achieved, opening up the application of these materials as nanocarriers for 
therapeutic purposes. In 2014, the Frey group showed that conjugating the MUC1 glycopeptide 
B-cell epitope and the tetanus toxoid T-cell epitope to the surface of hyperbranched 
polygycerol, enabled optimal presentation of antibodies due to the 3d topology of the branched 
structure.177 This synthetic vaccine led to significant immune responses in a mouse study, 
highlighting the potential of these systems to be used in anticancer immunotherapy. Haag and 
colleagues have further expanded these hyperbranched polyglycerols as drug delivery systems, 
by attaching enzymatically cleavable therapeutics to the surface of these nanocarriers.120 
Further work by the group has shown that conjugating doxorubicin via an acid cleavable 
hydrazine linker had high drug loadings (5-10 molecules per hyperbranched polymer of 2 – 5 
kg/mol) and an improved antitumour efficiency compared to free doxorubicin in a mouse 
tumour model.178  
 
Figure 5. Synthetic scheme and confocal laser scanning microscopy images of HeLa cells incubated 
with hyperbranched and self-immolative polymers conjugated with doxorubicin and cRGD peptide. 
Figure adapted with permission 118. Copyright 2015 American Chemical Society. 
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Hyperbranched and self-immolative polymers undergo a cascade depolymerisation process 
after stimuli responsive removal of a trigger at the focal point of the hyperbranched polymer. 
Liu and coworkers synthesisd hyperbranched self immolative polymers in a onepot AB2 
polycondensation method, after which, the polymer were funtionalised with various imaging, 
targeting, and therapeutic groups including, cRGD peptides, Doxorubicin, coumarin, choline, 
and DMAEMA for nucleic acid complexation.118 Depolymerisation triggered by blue light was 
investigated, and the polymer was determined to be completely degraded after 6 hours. 
Additionally intracellular release (HeLa cell-line) of doxorubicin conjugated to the exterior of 
the hyperbranched polymer was followed with confocal microscopy (Figure 5). Colocalisation 
studies indicated polymer cellular uptake via endocytosis and release of doxorubicin into the 
cytosol, which overtime was seen to enter the nucleus with use of acridine orange stain. 
Step growth polymerisation of ABn monomers, where n ≥ 3, has also been used to synthesise 
hyperbranched polymers for therapeutic delivery. For example, Zhu et al. synthesised 
biodegradable hyperbranched polyglycerol by in situ formation of an AB3 monomer, to which 
they then conjugated the anticancer drug methotrexate (MTX) and fluorescent dye 
rhodamine.121 The polymers showed good biocompatibility low cytotoxicity with over 90% 
NIH-3T3 cell viability after 48 hours over a polymer concentration range from 1 µg/mL to 10 
mg/mL, and biodegradability through the polymer ester bonds. MTT assay against a cancerous 
cell line suggested high anticancer efficiency of the hyperbranched polymer drug delivery 
system. 
 
3.3.2. Step growth polymerisation of A2+Bm monomers 
Synthesis of branched polymers via a double monomer methodology, A2 + Bm, is attractive due 
to the range of much more readily available monomers, however the approach can lead to 
gelation at high conversions and critical concentrations.34 These syntheses also require careful 
optimisation of the ratio of functional groups, monomer concentrations, purity of reagents, 
reaction time and temperature, in order to achieve controlled and reproducible reactions of high 
molecular weights without purification methods.168,179 The growth and final structure profile 
of A2 + Bm systems is also not fully comparable to ABn systems with their cascade type of 
branching patterns, leading to some in the community not considering them true hyperbranched 
polymers.33 
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A particularly simple but elegant step growth polymerisation method was developed by Lynn, 
Anderson, and Langer in the early 2000’s, involving Michael additions of amines to 
multifunctional acrylate groups to form poly(-aminoesters).180,181 This was further developed 
to hyperbranched poly(-aminoesters) by A2 + Bm routes more recently by a number of research 
groups. In 2016, Wang et al, investigated highly branched poly(-aminoesters) for gene 
therapy, synthesised by the Michael addition polymerisation of an A2 amine monomer with B3 
and B2 triacrylates and diacrylates.
124 The authors found that the branched polymer topology 
imparts favourable properties of improved transfection efficiencies and reduced toxicities in 
vitro. Additionally, the highly branched poly(-aminoesters) effectively delivered genetic 
material in vivo, and resulted in the expression of significant functional proteins in the skin. A 
similar strategy was employed by Oupicky and colleagues, who prepared hyperbranched 
poly(-amido amines) through the Michael addition polymerisation of and A2 diacrylamide 
monomer and a B3 amine monomer (Figure 6).
122 The polymers were degradable with a 
glutathione redox stimuli through use of a disulphide containing diacrylamide, and were also 
functionalised with fluorine moieties. Good ability to bind siRNA by the polymers was 
confirmed, and gene silencing was successfully demonstrated with an in vivo luciferase 
expressing tumor model. Against B16F10 cells and 4T1 cells, the fluorinated bioreducable 
hyperbranched polymer was able to knockdown luciferease expression the most (20-50% 
expression of luciferase relative to PBS control). While for the animal study, the same polymer 
siRNA formulation gave 10-40% expression of luciferase relative to PBS control, depending 
on whether lucerferase activity was determined in/ex vivo. 
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Figure 6. Hyperbranched poly(amido amines) and in vivo luc gene silencing (FRHB: fluorinated 
reducible hyperbranched polymer, RHB: reducible hyperbranched polymer, NHB: non-reducible 
hyperbranched polymer), a) bioluminescence images of mice with B16F10-luc tumours, b) 
quantification of whole-body images, c) ex vivo anaylsis of luc activity in isolated tumour samples. 
Figure adapted with permission 122. Copyright 2017 American Chemical Society. 
 
In a different example, the A2 + Bm system has also been recently employed to synthesise 
hyperbranched lysine based polymers that mimic cell-penetrating peptides. Chen et al. used a 
polycondensation reaction involving A2 + B3 + B2 monomers, and showed that the resulting 
hyperbranched polymers had high cellular internalisation rates which were dependent on pH.123 
The branched architectures enhanced the membrane lytic properties of the polymers compared 
to the linear version, and thus showed potential for cytoplasmic delivery of therapeutic 
molecules. 
 
3.3.3. Long chain hyperbranched polymers 
Hyperbranched polymers from macromolecular units are a particularly interesting class of 
dendritic polymer architecture due to the ability to introduce additional functionality along the 
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macromonomer chain, and the control over distance between branch points by tuning the 
degree of polymerisation of the linear macromonomer.89 Synthetic strategies involve 
combination of chain growth polymerisation methods to gain well-defined AB2 
macromonomers which can be further polymerised in an AB2 step growth method.  
Long chain hyperbranched PEG materials have been synthesised in this manner by Zhu and 
coworkers, and used for anticancer drug molecule delivery and plasmid DNA delivery.125 The 
researchers were able to combine the advantages of a long chain hyperbranched architecture 
with the favourable biological properties of PEG to produce promising branched materials for 
use as drug delivery systems. An alternative route to hyperbranched polymers has been 
developed by our group, utilising thiol-yne radical chemistry.95,139,182-184 This reaction involves 
the addition of a thiol to a reactive alkyne followed by the addition of another thiol to the 
resulting vinylthioether at a faster rate. This leads to hyperbranched polymers with very high 
degrees of branching. This approach can be used for both small molecules and polymers with 
thiol and alkyne end groups.185,186 In a recent study, we reported the synthesis of hyperbranched 
poly(ethyleneimine-co-oxazoline) by combination of thiol-yne photoaddition chemistry with 
well-defined linear ethyleneimine-co-oxazoline copolymers (Figure 7).126 This new PEI 
hyperbranched architecture with only secondary amines (compared to bPEI with primary, 
secondary, and tertiary amines) was used to complex and deliver plasmid DNA coding for 
GFP. In vitro toxicity assays and gene transfection experiments with HEK293T cell-line, 
highlighted the impact of polymer architecture, as the hyperbranched structure showed lower 
toxicity but similar transfection efficiencies compared to the equivalent linear p(ethyleneimine-
co-oxazoline) copolymers. The AB2 thiol-yne step growth approach to long chain 
hyperbranched polymers has also been employed by Dong et al., who synthesised 
hyperbranched polypeptide with a PEG shell for encapsulation and delivery of doxorubicin.128 
The researchers produced poly(e-benzyloxycarbonyl-L-lysine) with thiol and alkyne end 
groups which formed hyperbranched polylysine under UV irradiation, to which a linear PEG 
shell was attached. The hyperbranched polymer gave a higher drug loading than the linear 
counterpart block copolymer, and a slower drug release rate.  
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Figure 7. a) Hyperbranched p(ethyleneimine-co-oxazoline), with varying ethyleneimine contents from 
32% to 78%, by thiol-yne chemistry for use in the delivery of plasmid DNA with a GFP reporter gene, 
b) polymer toxicity as determined by XTT assay in HEK293T cells, c) proportion GFP positive cells 
and mean fluorescent intensities of transfected HEK293T cells compared to commercial branched PEI. 
Figure adapted with permission 126. Copyright 2019 Royal Society of Chemistry. 
 
3.4. Dendrimers 
 
Dendrimers are possibly the most studied of branched polymers for therapeutic delivery 
applications. This is due, in part, to their structurally perfect branching patterns and also to 
being very well defined unimolecular species.35 Poly(amido amine) (PAMAM) dendrimers 
were the first dendrimers to be widely studied and are now commercially available, in addition 
to the large variety in backbone structures and coupling chemistries that have since been 
developed.93 The dendrimer architecture offers the attractive property of multivalent surface 
functionality for increased interaction with biointerfaces, while also allowing efficient drug 
conjugation to the surface or encapsulation in the unimolecular micelle-like core. 
Anderson et al., employed a combinatorial approach to obtain a library of modified dendrimers 
of varying generation PAMAM and p(propylenimine) (PPI), with different alkyl chain 
substituents (C10 – C16).187 SiRNA formulated dendrimers were found to preferentially 
accumulate in Tie2-positive endothelial cells in the lung, when studied with an in vivo mouse 
model. The materials showed promise for the delivery of nucleic acid therapeutics in diseases 
or injuries involving dysfunctional endothelium, whilst having clinical translation advantages 
relating to molecularly defined dendrimer cores. Glutathione responsive PAMAM dendrimers 
have been developed by Kannan et al., and recently been investigated in a large animal model 
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of hypothermic circulatory arrest induced brain injury.133 Systemically injected dendrimer drug 
conjugates were able to deliver the antineuroinflamitory therapeutic N-acetyl cysteine, and the 
antiexcitotoxicity therapeutic valproic acid. The dendrimer delivery system produced 24 hr 
neurological score improvements of similar values to a 10 fold higher dose of free drug, and 
with much reduced adverse side effects. 
Another application of dendrimers in drug delivery, is the formulation of corticosteroids for 
the treatment of retinal neuroinflammation, in macular degenerative diseases. An intravitreal 
injection of hydroxyl-terminated polyamidoamine dendrimer covalently conjugated with 
fluocinolone acetonide, accumulated in activated microglia, and halted retinal degeneration for 
one month.188 Also in the realm of inflammation related diseases, the Hammond group recently 
showed that cationic and PEGylated PAMAM dendrimers with insulin-like growth factor 1 
conjugated to the 4-7 nm macromolecule surface, were able to penetrate cartilage and provide 
relief from osteoarthritic symptoms in an preclinical rat model. The size and surface charge of 
the nanocarrier was pivotal in achieving cartilage penetration and drug therapeutic lifetime.189 
In 2016, the group of Siegwart, reported modular and degradable dendrimers that had low 
toxicities and high antitumor efficiencies, and gave a significant survival benefit in the in vivo 
cancer model studied (Figure 8).190 The ester based dendrimers were synthesised using 
sequential thiol or amine Michael additions, which allowed a large library of dendrimers to be 
produced with differing functionalities and generations. Initial in vitro and in vivo siRNA 
luciferase gene silencing screens were performed to evaluate dendrimer candidates to be taken 
forward to a further aggressive liver cancer model. An optimal degradable dendrimer was 
identified that was able to inhibit growth in the studied cancerous tumour model, while having 
low toxicity and biodegradability. 
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Figure 8. Modular degradable dendrimers for therapeutic delivery to liver cancer, a) fluorescent 
imaging showing cancerous liver accumulation of siRNA, b) histology staining comnfirmed livers 
contained tumours, c) confocal imaging confirmed siRNA intracellular location. Figure adapted with 
permission 190. Copyright 2016 National Academy of Sciences. 
 
 
3.5. Branched-linear hybrid polymers 
 
As the field of branched and dendritic polymers has rapidly developed, new classes of hybrid 
polymers have emerged.90,191 These branched-linear hybrid polymer architectures can contain 
either dendrimers or hyperbanched polymers and include block copolymers, branched core star 
polymers, and dendronised polymers.  
 
3.5.1. Branched-linear block copolymers 
Hybrid block copolymer structures of branched polymers can be synthesised by either a chain 
first strategy, dendron/branched polymer first strategy, or a coupling strategy. A particular 
advantage of hybrid branched-linear block copolymers is the combination of branched 
topology traits with the self-assembly possibilities of block copolymers, which enables further 
development of drug delivery systems based on micelle like structures. This is illustrated by 
Hammond et al., who synthesised amphiphilic dendron-linear block copolymers with poly(-
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benzyl-L-aspartate) linear hydrophobic chain and hydrophilic polyester dendron unit 
functionalised with folate groups.135,192 The anticancer therapeutic paclitaxel was encapsulated 
in the micelle core with loading efficiencies of up to 40%, while the exterior of the drug carrier 
presents a multivalent targeting by the folate groups. Both targeted and non-targeted micelles 
accumulated in tumour sites by the EPR effect after injection in mice, however the folate 
system was able to enter tumour cells from the extracellular environment by receptor mediated 
endocytosis, and had a 4 fold improved anticancer efficiency compared to the non-targeted 
system. 
The Luo group has investigated amphiphilic dendritic-linear copolymers for anticancer drug 
delivery (Figure 9).134,193 The synthesised polymers form micelles having a hydrophilic linear 
PEG shell and hydrophobic dendron core functionalised with rhein, or cholic acid, or 
riboflavin, which are able to bind to the drug doxorubicin thus forming stable nanoparticles. 
The strong doxorubicin dendron interactions leads to very high drug loading efficiencies of up 
to 100% immediately after formulation, reducing to between 100% - 40% after 1 day, and 
further reducing to 100% - 10% after 1 week. The dendritic-linear polymer systems 
investigated formed particles with high stabilities, long circulation times, reduced toxicities, 
whilst also showing favourable anticancer efficiencies in the particular subcutaneous Raji 
lymphoma xenograft mouse model that was employed. 
 
 
Figure 9. Dendritic-linear hybrid block copolymers for doxorubicin delivery, synthesised by a rational 
design and high throughput development process. Figure reproduced with permission 134. Copyright 
2015 Springer Nature. 
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Shen et al., studied dendritic-linear block copolymers for delivery of camptothecin.136 The 
therapeutic agents were conjugated to the hydrophobic dendron segment of the polymer via a 
redox responsive disulphide bridge, while the linear PEG segment provided solubility and 
biocompatibility. Due to the active ingredient being covalently attached to the multivalent 
dendron, high drug loadings were achieved. The polymer drug conjugate self-assembled into 
micelles of different morphologies depending on the number of conjugated drugs and thus the 
hydrophobicity of the core forming block. It was found that medium length rod-like micelles 
of these branched-linear block copolymers had long circulation times, and released 
camptothecin intracellularly, demonstrating the advantages of branched-linear block 
copolymers for therapeutic delivery to tumours. 
 
3.5.2. Branched-core star polymers 
Star polymers involving linear polymer chains extending radially from a globlular three 
dimensional branched polymer, are another interesting class of branched-linear hybrid 
polymers. This polymer architecture can be rationally designed for use as efficient 
encapsulation devices for various guest molecules, as well as direct conjugation to the star 
exterior. In cases where a high number of polymer arms can be attached to the branched 
polymer core, the star polymer can act as a unimolecular nanocarrier.36,194 When considering 
amphiphilic core shell systems with high number of arms, the architecture can offer the 
advantage of not dissembling into individual polymer chains upon dilution, as would be the 
case for micelle systems. However, there are also studies looking at the self-assembly of star 
polymers with low number of arms. 
Branched core star polymers have been investigated as nucleic acid delivery vehicles by a 
number of research groups, either utilising cationic branched cores or cationic linear polymer 
shells for electrostatic complexation of the therapeutic payload. Gong and colleagues utilised 
a hyperbranched polyester core (Boltron H40) coupled with linear cationic polymer arms 
through pH sensitive imine bonds, to complex and deliver siRNA to GFP expressing triple 
negative breast cancer cells in vitro.138 The linear polymer arms consisted of poly(aspartic acid) 
with disulphide linked 2-aminoethyl groups for nucleic acid complexation and also disulphide 
linked imidazole groups to promote endosomal escape. This RNA delivery system showed 
GFP down regulation capabilities comparable to commercial transfection reagents but with 
lower toxicity, particularly when further functionalised with GE11 targeting peptide and tested 
on EFGR overexpressing cell-lines. In contrast, Matyjaszewski et al. investigated cationic core 
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star polymers, synthesised in an one pot ATRP approach, for siRNA complexation and cellular 
uptake.142,195 While Wang and coworkers synthesied star polymers combining a branched PEI 
core and linear poly(-amino ester) arms.141 This star poly(-amino ester) showed excellent 
gene transfection efficiencies of primary rat adipose derived mesenchymal stem cells, of 
between 200 and 15000 times higher than either the PEI core, or the poly(-amino ester) arms 
on their own.  
Similar bPEI core star polymers have been synthesised by the Voit group for small molecule 
encapsulation, who employed an oligosaccharide shell to stabilise the PEI structures.196 The 
researchers studied encapsulation efficiencies of the branched core star polymers with various 
small molecules of different overall charges, including vitamin-B, an estradiol derivative, and 
pantoprazole. Interestingly, the core shell glycopolymer architecture was found to be necessary 
for stable electrostatic complexes. They obtained high encapsulation efficiencies of up to 10 
drug molecules per macromolecule, and the maltriose polymer in particular showed good 
potential for use as a drug delivery system. Cationic core star polymers have been used to 
deliver platinum based anticancer drugs with high efficiencies, by Nie, Wang, and 
colleagues.197 PAMAM dendrimers were conjugated with platinum prodrug, and poly(ethylene 
glycol)-block-(2-azepane ethyl methacrylate) linear polymer arms, which had pH based size 
switching behaviour for enhanced tumour penetration and drug delivery in vivo. 
Another option for small molecule drug delivery with branched core star polymers, is to employ 
an amphiphilic system to either conjugate or encapsulate hydrophobic molecules. Amphiphillic 
star based hyperbranched Boltron H40 has been used by a number of research groups for both 
encapsulation and drug conjugation.140,198 A hydrophilic linear polymer such as PEG is 
typically used as the hydrophilic shell. Our group has recently utilised amphiphilic branched 
core star polymers for hydrophobic molecule encapsulation and cellular internalisation.139 A 
hydrophilic and biocompatible poly(2-ethyl oxazoline) shell was conjugated to a hyperbanched 
and hydrophobic polyester core polymer that was based on a thiol-yne polymerisation system. 
The core shell architecture allowed encapsulation of hydrophobic Nile Red as a model drug, 
and the polymers were readily uptaken by A2780 ovarian cancer cells via an energy dependent 
mechanism, suggesting endocytosis. 
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3.5.3. Dendronised polymers 
Dendronised polymers (linear polymers grafted with dendrons), and hypergrafted polymers 
(linear polymers grafted with hyperbranched polymers) are hybrid polymer architectures which 
have only more recently been established for use in therapeutic delivery.191 The first study 
evaluating rigid-rod dendronised polymer toxicity, biodistribution, and pharmacokinetics in 
vivo, was undertaken by Fréchet and Szoka.144 The materials comprising a poly(4-
hydroxystyrene) backbone with 4 generation polyester dendrons were evaluated for 
cytotoxicity against MDA breast cancer cells in vitro, which displayed 70% viablilty at a 
polymer concentration of 3 mg/mL. In vivo biodistribution studies were performed with 
tumoured and non tumoured mice. The smaller molecular weight dendronised polymers (67 
kDa) exhibited urinary excretion, the largest polymer (1740 kDa) was cleared by the 
reticuloendothelial organs, while the medium molecular weight system (251 kDa) accumulated 
the most in tumour environments. The long blood circulation times of the dendronised 
polymers was attributed to their large molecular weights and rigid-rod shapes.  
Dendronised amphiphilic polymers have been synthesised using an alkyne azide click reaction 
to graft polyglycerol dendrons to a PEG based linear backbone.145 The systems formed 
supramolecular aggregates able to efficiently encapsulate hydrophobic guest molecules, and 
then be internalised by cells as followed by flow cytometry and confocal microscopy. In 
addition, the polyglycerol shell imparted non-cytotoxic properties to the nanocarriers over a 
range of concentrations, and the dendronised polymers performed better than similar linear-
dendron block copolymers which could be destabalised at lower concentrations. 
Gu et al. investigated in vivo doxorubicin delivery using a dendronised heparin based polymer 
system.143 The researchers utilised a pH sensitive hydrazine bond to conjugate doxorubicin to 
a lysine based Dendron, which was then attached to a linear heparin chain with the use of azide 
alkyne cycloaddition chemistry. Drug loadings of 9 wt% could be achieved and the polymer 
architecture further self assembled into nanoparticles of around 100 nm. In a mice 4T1 breast 
tumour model the polymer delivery system produced strong antitumour results, high 
antiangiogenisis effects, and apoptosis compared to the free drug as observed by a variety of 
mice and tumour weight analysis, immunohistochemical analysis, and histology. 
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Figure 10. Dendronised heparin-doxorubicin conjugates as a pH responsive therapeutic delivery 
system, including in vivo studies showing a) relative tumour volumes, b) mouse body weights, c) tumour 
size analysis, and d) tumour weight analysis. Figure adapted with permission 143. Copyright 2013 
Elsevier. 
 
Dendronised polymers have also been used for gene delivery applications. Guon et al. 
synthesised a range of biodegradable dendronised polypeptides with variations in structure that 
were tuned in order to identify superior delivery vectors.199 A dendronised polymer based on a 
second generation lysine dendron functionalised with 75% histidine and 25% tryptophan, was 
found to have the optimal combination of charged and aromatic residues required for successful 
delivery. The polymers showed good efficiencies when complexed with siRNA to eGFP 
expressing NIH-3T3 cells in vitro, while also exhibiting minimal toxicity. 
 
4. Architecture property relationships 
With increased access to complex polymer architectures through new chemical technologies, 
researchers have been able to start hypothesising relationships between polymer architecture 
and subsequent properties as therapeutic delivery systems as well as physiochemical properties. 
The physiochemical properties of linear polymers are largely determined by the monomer 
repeat unit, however the properties of branched polymers result mainly from the polymer end 
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groups at the surface of the polymer.33 The biocompatibility cytotoxicity of polymers is a 
complex assessment and is mainly affected by non-architecture related factors such as polymer 
functionality, however branched structures can offer ability to modulate biocompatibility 
toxicity to cells. Known toxic molecules or functionalities can be embedded within the core of 
branched topologies, and new polymer architectures could be used to alter the protein corona 
by recruiting or repelling specific endogenous biomolecules to polymer surfaces by variation 
branching densities.200 Polymer toxicity is also known to be affected by polymer flexibility 
with a number of studies reporting reduced toxicity for branched polymer systems.29 The 
globular and approximately spherical conformation of branched polymers in solution is a 
significant attraction for drug delivery applications. This size and shape of polymers is an 
important parameter and can alter significantly the final properties of the delivery system, in 
particular, whether the polymer forms unimolecular and stable objects, or forms larger self-
assembled structures, which in turn impacts the circulation times and biodistribution of the 
polymer systems.201,202 The tunability of polymer architecture and shape offers opportunities 
to increase drug loading either through manipulating the polymer core or self-assembled 
structure, or by the increased number of functionalisable groups on the exterior of a branched 
polymer.36 When considering in vivo therapeutic delivery barriers, branched polymers offer 
opportunities for stimuli responsive endosome escape by proton sponge/osomotic pressure 
changes and subsequent polymer swelling of charge alteration.203 Cellular uptake has also been 
reported to depend on polymer architecture, with increased branching potentially resulting in a 
higher number of multivalent interactions with cell surface receptors, thereby increasing 
internalisation. 
 
5. Conclusions and future perspectives 
 
New developments in the preparation and application of polymer materials in therapeutic 
delivery, have been helped by the combined efforts of chemists, biologists, materials scientists, 
and clinicians. The overall goal of scientists in this field is to improve or maximise the 
therapeutic effect while minimising unwanted or toxic side effects of the active ingredient. The 
ability to synthesise increasingly complex architectures has opened up a number of exciting 
avenues of research involving new classes of polymers. This review outlined and compared 
different branched polymer architectures and their application in therapeutic delivery in an 
accessible manner, with the aim of appealing to a multidisciplinary audience. Highly branched 
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polymers, synthesised by chain growth polymerisation strategies including SCVP or divinyl 
monomer copolymerisation, are highly functional materials from facile onepot routes. These 
materials have seen increasing use in therapeutic formulation applications, particularly since 
the development of the controlled radical polymerisation methods in the late 1990s. 
Hyperbranched polymers from step growth polymerisations have also seen wide employment 
in drug delivery systems. New branched-linear hybrid architectures are starting to be explored 
by researchers. These exciting materials, able to be synthesised with efficient coupling 
chemistries, enable the combination of favourable aspects of branched polymers with the 
ablility to create precise amphiphilic polymers for drug encapsulation/conjugation. The 
capability to synthesise and characterise well-defined polymer architectures could help to 
further examine structure-function correlations in the field of polymer based therapeutic 
delivery. The translation of the potential of polymer-based therapeutic delivery systems from 
successful in vivo laboratory studies to efficacy in humans, remains problematic. Current 
regulations from bodies including the US Food and Drug Administration, and the European 
Medicines Agency, are a limitation for the translation of branched and dendritic polymer 
architectures into therapeutic products. Polymers have molecular weight distributions that do 
not fit regulations for drug products. In this regard, dendrimers, being single molecular weight 
species, have seen more products enter clinical trials and be commercialised than other 
branched polymer architectures. The Australian company Starpharma Ltd (which also funded 
and then acquired the Donald Tomalia founded Dendritic Nanotechnologies Ltd in 2006), has 
developed an antimicrobial dendrimer based gel product, and has a dendrimer 
chemotherapeutic delivery system in clinical trials, is leading the way in clinical translation. 
The scope for combining advances in polymer science and associated developments in 
dendritic architecture synthesis, with increasing knowledge of disease heterogeneity and 
limitations of certain animal models, suggests further improvements in translation will be 
realized over the coming decades. 
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